Fact based stock research
Southwest Pharmaceutical (SHSE:600666)


Southwest Pharmaceutical stock research in summary

swp.cn


Southwest Pharmaceutical shares have a SELL rating. While they are safely financed, they show below average growth, and are bad value. We recommend selling Southwest Pharmaceutical shares.


Latest Obermatt Ranks


Country China
Industry Pharmaceuticals
Index SSE Composite
Size class Small

June 8, 2018. Top 10 stocks updated on Top 10 schedule or at least quarterly. ()


Research History: Southwest Pharmaceutical

STOCK RESEARCH SUMMARY 2015 2016 2017 2018
STOCK VALUE RANKS
9
9
9
STOCK GROWTH RANKS
75
100
12
STOCK SAFETY RANKS
30
30
67
COMBINED STOCK RANKS
28
28
12

Last update of Combined Rank: 8-Jun-2018. Stock research history is based on the Obermatt Method. The higher the rank, the better is Southwest Pharmaceutical in the corresponding investment strategy.


Value Metrics in Detail

Last update of Value Rank: 8-Jun-2018. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Southwest Pharmaceutical; except for dividend yield where the rank is higher, the higher the yield.


Growth Metrics in Detail

GROWTH METRICS 2015 2016 2017 2018
REVENUE GROWTH
82
83
8
PROFIT GROWTH
28
28
12
STOCK RETURNS
9
66
75
CONSOLIDATED RANK: GROWTH
75
100
12

Financial reporting date of Growth Rank: 31-Mar-2018. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Southwest Pharmaceutical.


Safety Metrics in Detail

SAFETY METRICS 2015 2016 2017 2018
LEVERAGE
37
38
34
REFINANCING
39
36
62
LIQUIDITY
51
50
67
CONSOLIDATED RANK: SAFETY
30
30
67

Financial reporting date of Safety Rank: 31-Mar-2018. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Southwest Pharmaceutical and the more cash is available to service its debt.


Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Southwest Pharmaceutical from June 8, 2018.